We See
New Ways To
A Healthier
Vision
THE GRAYBUG VISION
We work relentlessly to save sight through transformative science, creating solutions to treat vision-threatening diseases, that improve quality of life and care for all involved.
THE DISEASES WE SOLVE FOR
Approximately 80 million Americans are affected by potentially blinding eye disease and this number is projected to double by 2030 based on an aging population and the increasing prevalence of diseases that can cause vision loss.
Age-Related Macular Degeneration
10-15%
Have active blood vessel growth and leakage, or wet AMD
Age-Related Macular Degeneration (AMD)
About 11 million people in the US and 170 million people worldwide have AMD, a leading cause of vision loss in the elderly, of which 10-15% have active blood vessel growth and leakage, or wet AMD.
Geographic Atrophy
42%
OF PATIENTS are legally blind with a visual acuity of 20/200
Geographic Atrophy (GA)
GA affects more than 5 million people globally, and more than 100,000 new cases are diagnosed each year. 42% of GA patients are legally blind with a visual acuity of 20/200.
Diabetic Retinopathy
10M
DIABETIC PATIENTS IN the US suffer from This vision- threatening disease
Diabetic Retinopathy (DR)
About 10 million people in the United States and more than 90 million worldwide suffer from DR. DR is a leading cause of acquired vision loss in the young and middle-age adult population. It is estimated that the number of patients with DR will increase globally to over 190 million by 2030.
Retinitis Pigmentosa
1 / 4,000
People WILL EVENTUALLY LOSE MOST OF THEIR SIGHT
Retinitis Pigmentosa (RP)
Among inherited retinal diseases, adult-onset Retinitis Pigmentosa (RP) is the most common, with a worldwide prevalence of approximately 1 in 4,000 people. It can result in severe vision impairment or blindness.
Glaucoma
2.7 / 76
Million
us
us
Million
worldwide
worldwide
Glaucoma
Glaucoma affects approximately 2.7 million people in the US and 76 million worldwide. It is one of the most common ophthalmic disorders characterized by the progressive degeneration of the optic nerve that leads to visual impairment.
Corneal Clouding
80-98%
of patients suffering
from MPS1
from MPS1
Corneal Clouding
Corneal clouding affects over 80% of MPS1 patients (mainly children), and up to 98% of patients with the most severe
form of MPS1. MPS1 is considered an ultra-rare disease affecting 1 in 100,000 people worldwide.
Our Proprietary Technologies
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. Our diversified portfolio is designed to treat vision-threatening diseases of the retina, optic nerve, and cornea, by either maintaining effective drug levels in ocular tissues for long periods of time, using innovative technologies such as injectable sustained-release formulations, or by curing diseases with gene therapies.
Our gene therapy APPROACH
Our sustained-release formulation technologies
Microparticle technology
Our sustained-release formulation technologies
Implant Technology
OUR PIPELINE
Based on our proprietary technologies, our R&D pipeline targets a range of chronic vision-threatening diseases, some of which have no viable treatment option.
GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy.
GB-102
GB-401 is a first-in-class implant formulation containing a novel prodrug of timolol for the treatment of primary open angle glaucoma (POAG) designed for a twice-per-year intravitreal injection with a proprietary applicator.
GB-401
GB-501 is an adeno-associated virus (AAV) gene therapy with Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to treat corneal clouding caused by Mucopolysaccharidosis Type 1 (MPS1), a lysosomal storage disorder.
GB-501
GB-601 is being developed as a long-acting formulation of a novel cGMP analog to address hereditary retinal diseases like Retinitis Pigmentosa, a group of genetic disorders that involve a loss of cells in the retina.
GB-601
GB-701 is being developed as a long-acting formulation of a potent factor B inhibitor targeting the complement cascade which plays a role in AMD.
GB-701
What Drives Us
“We make bold moves for the benefit of patients.
Fred Guerard, PharmD, CEO
We are curious, resilient and don’t give up easily.
We thrive on the diversity of opinions and beliefs.
Which values guide you through life?”
“The power of science means nothing until you see the impact it can have on people’s lives. Our singular focus is to deliver transformative medicines for patients suffering from vision-threatening diseases, and we do it in partnership with them.”
Parisa Zamiri, MD, PhD, CMO
MORE THAN 10 Years of
Vibrant Vision
Vibrant Vision
Since 2011, we have been dedicated to transformative science making healthy vision more accessible and manageable for patients with chronic vision-threatening eye diseases. Watch the video to learn about how it all started, what drives us, and what our vision for the future looks like.